5 Key Takeaways

• 1

  Sartorius launched the Eveo Cell Therapy Platform to enhance the scalability of autologous cell therapies like CAR-T.

• 2

  The platform integrates multiple processes into a closed, modular workflow, allowing parallel processing of patient batches.

• 3

  In a pilot, a single operator processed eight patient batches in a space typically used for two, significantly increasing output.

• 4

  Sartorius estimates the platform could produce over 350 doses annually, reducing CAR-T manufacturing costs by about 90%.

• 5

  Orders for the Eveo Cell Therapy Platform will begin in September 2026, with deliveries expected in 2027.